A Unique Subset of Epithelial Ovarian Cancers With Platinum Sensitivity and PARP Inhibitor Resistance

Cancer Research - United States
doi 10.1158/0008-5472.can-14-2593
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

RING Domain–deficient BRCA1 Promotes PARP Inhibitor and Platinum Resistance

Journal of Clinical Investigation
Medicine
2016English

PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

An Effective Epigenetic-Parp Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations

Clinical Cancer Research
Cancer ResearchOncology
2018English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated With PARP Inhibitor Resistance

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2 -Mutated Carcinomas

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer

2019English

Layer‐by‐Layer Nanoparticles for Novel Delivery of Cisplatin and PARP Inhibitors for Platinum‐Based Drug Resistance Therapy in Ovarian Cancer

Bioengineering & Translational Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy